³ÉÈË´óƬ

According to the , two in five Canadian adults are expected to develop cancer in their lifetimes. While significant strides have been made to increase survival rates, cancer remains a leading cause of death in Canada and around the world. On World Cancer Day we reflect on some of the recent advances our faculty, staff, and student researchers have made, furthering our understanding of cancer and their ground-breaking efforts to improve treatment, access, and care in our local, national, and global communities. As leaders in interdisciplinary health and wellness, Queen’s researchers are driving progress and innovation in novel therapies, health practice, and health policy.

Ground-breaking innovation

New blood test helps with earlier cancer detection and better treatment

(Queen’s Cancer Research Institute) has led a team of researchers at Queen’s in developing a new detection, mDETECT, and characterization method that is a more sensitive means of detecting and monitoring the presence of cancer and allowing for real time monitoring of a patient’s response to chemotherapy to optimize treatment.

Trialled and true

The , based at Queen’s University, plays a critical role in the fight against cancer by designing and administering clinical trials in cancer therapy, supportive care, and prevention across Canada. Since its establishment in 1980, CCTG has supported more than 600 phase I-III trials enrolling approximately 100,000 patients from 40 countries on six continents. At any given time, CCTG has 60 to 70 active clinical trials.

Advancing cellular therapy

(Canadian Cancer Trials Group; Medicine) and (McMaster University) have received more than $5 million to develop a national cellular therapy translation research platform. ExCELLirate Canada will develop cell therapies as safe and viable treatment options through identifying biological mechanisms affecting safety and designing cost-effective methods for the harvest, expansion, manipulation, purification, and delivery of the cells.

Predicting cancer spread with natural language processing

Canada Research Chair in Biomedical Computing and Informatics Amber Simpson (Computing; Biomedical and Molecular Sciences) and (Computing) with radiologist of are developing technology that will relieve the issues that come from gathering data from CT scans and can predict how cancer will spread in patients using natural language processing.

Advancing health equity

Inuit cancer patients often face difficult decisions without support far from home

In The Conversation Canada, (Rehabilitation Therapy), (Rehabilitation Therapy), and partners from the and discuss their aims to understand the experiences of Inuit who travel from remote to urban settings for cancer care and the health and social inequities this group faces in accessing healthcare.

Do randomized cancer trials truly reflect the global burden of cancer?

A study led by Canada Research Chair in Populations Cancer Care Christopher Booth (Oncology; Public Health Sciences) with (Public Health Sciences; Oncology) and (Global Health; Oncology) found that controlled trials disproportionately study breast cancer while other cancers, including cervix, gastroesophageal and pancreas, are under-represented even though they account for a substantial proportion of global cancer death.

Why cancer care isn’t ‘one-size-fits-all’ from one country to another

(Oncology) was a co-lead author of a policy review in Lancet Oncology that designed a checklist to allow countries to establish a baseline of existing cancer prevention, diagnosis, and treatment resources and to support strategies to actively encourage access to care for their underserved populations.  

(Nursing) led a study to better understand how older cancer survivors are coping during the COVID-19 pandemic. Participants were able to make recommendations on how they believe their care could have been improved and suggest opportunities for innovation moving forward.

Access to essential cancer medicines is unequal globally

Research from (Oncology; Public Health Sciences) with collaborators at the World Health Organization (WHO) in Lancet Oncology asked oncologists worldwide to list the most important cancer medicines and to describe whether patients could access these medicines in their home country.

Pioneering leadership

International leadership in cancer recognized with 2021 Gairdner Award

, Professor Emerita (Oncology; Medicine), received the for her dedication to transforming the fields of cancer clinical trials and cancer drug delivery.

Queen’s health researcher receives inaugural Canadian Cancer Society Lifetime Contribution Prize

, Professor Emeritus (Medicine; Oncology) and inaugural director of the Canadian Cancer Trials Group, received the for his contributions, vision, and leadership in enhancing the Canadian cancer research landscape to significantly benefit the lives of people with cancer.